Synthesis and anti-platelet aggregation activity evaluation of ligustrazine H2S donor derivatives was written by Luo, Bi-lan;Liu, Zi-bing;Li, Yi;Zhao, Ju-qin;Li, Yong;Zhang, Yi;Tang, Lei;Fan, Ling-ling. And the article was included in Huaxue Shiji in 2020.Application of 628-13-7 This article mentions the following:
Based on the principles of the combination and bioisosterism, three ligustrazine H2S donor derivatives were designed and synthesized by substitution, cyclation, oxidation, esterification and etherification reactions using 4-hydroxyacetophenone and ligustrazine as the starting materials. The structures were confirmed by 1HNMR, 13CNMR and HR-MS. The in vitro anti-platelet aggregation activities of the target compounds have been preliminarily tested by the Born turbidimetric method, and the exptl. results showed that 4-(3-thioxo-3H-1, 2-dithiol-5-yl) phenyl-3,5,6-trimethylpyrazine-2-carboxylate shown in I (IC50=1.16 mmol/L) had significant inhibitory activity for ADP induced platelet aggregation, which was better than clin. drugs ligustrazine, 3-n-butylphthalide, edaravone and aspirin. Therefore, it may be used as a potential candidate for the treatment of cardiovascular and cerebrovascular disease. In the experiment, the researchers used many compounds, for example, Pyridinehydrochloride (cas: 628-13-7Application of 628-13-7).
Pyridinehydrochloride (cas: 628-13-7) belongs to pyridine derivatives. The pyridine ring occurs in many important compounds, including agrochemicals, pharmaceuticals, and vitamins. One of the examples of pyridines is the well-known alkaloid lithoprimidine, which is an A3 adenosine receptor antagonist and N,N-dimethylaminopyridine (DMAP) analog, commonly used in organic synthesis.Application of 628-13-7